Neurology Publish Ahead of Print
DOI: 10.1212/WNL.00000000000012301

Teaching NeuroImages: Central Pontine Myelinolysis in Diabetic Ketoacidosis

Natalia Gonzalez Caldito¹, Nurose Karim¹, Mehari Gebreyohanns¹

¹Department of Neurology & Neurotherapeutics, University of Texas Southwestern Medical
Center, Dallas, TX, USA

Neurology® Published Ahead of Print articles have been peer reviewed and accepted for publication. This manuscript will be published in its final form after copyediting, page composition, and review of proofs. Errors that could affect the content may be corrected during these processes.

Search terms: Central pontine myelinolysis, osmotic demyelination syndrome, pons, brainstem, metabolic diseases.

Submission type: Teaching NeuroImage (resident & fellow section)

Title character count (with spaces): 54

Number of tables: N/A

Number of figures: 1

Word count abstract: N/A

Word count of manuscript: 150

Corresponding author: Mehari Gebreyohanns, MD, FAHA, FAAN,
mehari.gebreyohanns@utsouthwestern.edu

Disclosure

Natalia Gonzalez Caldito, Nurose Karim, and Mehari Gebreyohanns report no disclosures relevant to the manuscript.

Written consent was not obtained.

DESCRIPTION

Central Pontine Myelinolysis (CPM) is a clinically heterogeneous neurological disorder of demyelination in the pons, usually from rapid correction of hyponatremia.^{1,2}

A 38-year-old woman with uncontrolled type 1 DM (hbA1c 12.8%) was admitted for diabetic ketoacidosis (731mg/dl blood glucose). Hyperglycemia was corrected within 24 hours to 129mg/dl. Upon presentation, the sodium and potassium levels were 139 and 3.9 mmol/L respectively, remaining stable until discharge. There was no history of malnutrition nor alcohol abuse.

Four days later, she developed acute diffuse pyramidal weakness. Brain MRI revealed symmetric restricted diffusion in the pons with a normal MR angiography (Figure 1). She remained stable and was discharged to a rehabilitation facility.

Diabetic ketoacidosis is an uncommon cause of CPM with uncertain physiopathology.³ Here, it is plausible that a rapid drop in osmolality in a chronic state of high osmolality (uncontrolled DM) lead to CPM. A slower correction of hyperglycemia could have possibly prevented it.

Appendix 1. Authors

Name	Location	Contribution
Natalia Gonzalez Caldito, MD	University of Texas Southwestern Medical Center	Patient management, literature review, gathered data and drafted the manuscript for intellectual content
Nurose Karim, MD	University of Texas Southwestern Medical Center	Patient management and revised the manuscript for intellectual content
Mehari Gebreyohannis, MD	University of Texas Southwestern Medical Center	Patient management and revised the manuscript for intellectual content

Acknowledgements: N/A

BIBLIOGRAPHY

1. Fitts W, Vogel AC, Mateen FJ. The changing face of osmotic demyelination syndrome: A retrospective, observational cohort study. *Neurology: Clinical Practice*. Epub ahead of print 26 August 2020. DOI: 10.1212/CPJ.0000000000000932.
2. Rodríguez-Velver KV, Soto-Garcia AJ, Zapata-Rivera MA, et al. Osmotic Demyelination Syndrome as the Initial Manifestation of a Hyperosmolar Hyperglycemic State. *Case Reports in Neurological Medicine* 2014; 2014: e652523.
3. Matías-Guiu JA, Molino ÁM, Jorquera M, et al. Pontine and extrapontine myelinolysis secondary to glycemic fluctuation. *Neurologia* 2016; 31: 345–347.

Figure 1: Central pontine myelinolysis in diabetic ketoacidosis

T2-FLAIR revealing symmetric hyperintensities centered in the pons (A) with restricted diffusion (B). T1 post contrast with gadolinium demonstrated no enhancement(C).

FLAIR: fluid-attenuated inversion recovery; DWI: diffusion-weighted magnetic resonance imaging; Post GAD: post gadolinium. MRI: Magnetic Resonance Imaging

Neurology®

Teaching NeuroImages: Central Pontine Myelinolysis in Diabetic Ketoacidosis

Natalia Gonzalez Caldito, Nurose Karim and Mehari Gebreyohannis

Neurology published online June 2, 2021

DOI 10.1212/WNL.00000000000012301

This information is current as of June 2, 2021

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/early/2021/06/02/WNL.00000000000012301.citation.full
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): All Clinical Neurology http://n.neurology.org/cgi/collection/all_clinical_neurology All Demyelinating disease (CNS) http://n.neurology.org/cgi/collection/all_demyelinating_disease_cns All Medical/Systemic disease http://n.neurology.org/cgi/collection/all_medical_systemic_disease Endocrine http://n.neurology.org/cgi/collection/endocrine MRI http://n.neurology.org/cgi/collection/mri
Permissions & Licensing	Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2021 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.